What Happened?
New Haven, AB-based Trevi-Therapeutics Appointed Jennifer Good as President and Chief Executive Officer
About the Company
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
About the Person
Jennifer Good is President and Chief Executive Officer at Trevi Therapeutics. Previously, Jennifer held various senior HR leadership roles in the industry.
Info Source
News
Short Profile